- Home
- JZXN vs COCP Comparison
JZXN vs COCP Comparison
Compare JZXN & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JZXN | COCP |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 15.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | JZXN | COCP |
|---|---|---|
| Price | $2.62 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 92.2K |
| Earning Date | 03-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,465.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $0.86 |
| 52 Week High | $312.80 | $2.67 |
Technical Indicators
Market Signals| Indicator | JZXN | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 45.31 |
| Support Level | $1.03 | $0.86 |
| Resistance Level | $2.01 | $0.99 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 80.90 | 47.47 |
Price Performance
Historical ComparisonAbout JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).